Skip to main content
NASDAQ:CRNX

Crinetics Pharmaceuticals News Headlines

$16.22
+0.32 (+2.01 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.61
$16.50
50-Day Range
$15.28
$17.97
52-Week Range
$11.61
$23.70
Volume71,574 shs
Average Volume132,532 shs
Market Capitalization$609.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

Headlines

Crinetics Pharmaceuticals (NASDAQ CRNX) News Headlines Today

SourceHeadline
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $16.96Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $16.96
americanbankingnews.com - May 10 at 4:38 PM
Zacks: Analysts Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to Post -$0.64 EPSZacks: Analysts Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to Post -$0.64 EPS
americanbankingnews.com - May 10 at 12:00 PM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by JonestradingCrinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Jonestrading
americanbankingnews.com - May 10 at 8:36 AM
FY2022 Earnings Forecast for Crinetics Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRNX)FY2022 Earnings Forecast for Crinetics Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRNX)
americanbankingnews.com - May 9 at 3:40 AM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly  Earnings Results, Misses Expectations By $0.03 EPSCrinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
americanbankingnews.com - May 7 at 3:14 PM
Cantor Fitzgerald Comments on Crinetics Pharmaceuticals, Inc.s FY2022 Earnings (NASDAQ:CRNX)Cantor Fitzgerald Comments on Crinetics Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:CRNX)
americanbankingnews.com - May 7 at 9:24 AM
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateCrinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
in.finance.yahoo.com - May 6 at 7:22 PM
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateCrinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 6 at 7:22 PM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Research Coverage Started at JonestradingCrinetics Pharmaceuticals (NASDAQ:CRNX) Research Coverage Started at Jonestrading
americanbankingnews.com - May 3 at 1:22 PM
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Buy" from BrokeragesCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - May 3 at 9:14 AM
 Brokerages Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to Announce -$0.65 Earnings Per Share Brokerages Anticipate Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to Announce -$0.65 Earnings Per Share
americanbankingnews.com - April 23 at 12:16 AM
Crinetics Pharmaceuticals Stock Is Showing Strong Insider InterestCrinetics Pharmaceuticals Stock Is Showing Strong Insider Interest
finance.yahoo.com - April 21 at 1:34 PM
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.55Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $16.55
americanbankingnews.com - April 21 at 12:54 PM
What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?What Type Of Shareholders Own The Most Number of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
finance.yahoo.com - April 12 at 8:50 AM
Insider Buys Crinetics Pharmaceuticals SharesInsider Buys Crinetics Pharmaceuticals Shares
benzinga.com - April 9 at 1:25 PM
Crinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call PresentationCrinetics Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 31 at 12:35 AM
Crinetics Pharmaceuticals, Inc. to Host Earnings CallCrinetics Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 30 at 6:32 PM
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial ResultsCrinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 30 at 6:32 PM
Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial ResultsCrinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
benzinga.com - March 24 at 7:35 AM
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical ProgramsCrinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
finance.yahoo.com - March 12 at 4:56 PM
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushings Disease (CRN04894) Advances into Phase 1 StudyCrinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease (CRN04894) Advances into Phase 1 Study
benzinga.com - February 5 at 6:35 PM
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 StudyCrinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
finance.yahoo.com - February 4 at 7:55 AM
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 StudyCrinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
markets.businessinsider.com - February 3 at 9:57 AM
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 StudyCrinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
finance.yahoo.com - February 3 at 9:57 AM
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare ConferenceCrinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
theglobeandmail.com - January 7 at 7:09 PM
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare ConferenceCrinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 7:53 AM
Heres Why Were Not Too Worried About Crinetics Pharmaceuticals (NASDAQ:CRNX) Cash Burn SituationHere's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
finance.yahoo.com - December 27 at 9:39 AM
Is CRNX A Good Stock To Buy Now?Is CRNX A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 12:27 AM
Crinetics Pharmaceuticals to Participate in December Investor ConferencesCrinetics Pharmaceuticals to Participate in December Investor Conferences
finance.yahoo.com - November 23 at 8:37 AM
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical EndocrinologyCrinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
finance.yahoo.com - November 16 at 8:22 AM
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine  for the Treatment of AcromegalyCrinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
finance.yahoo.com - November 13 at 12:31 PM
Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings?Should You Buy Crinetics Pharmaceuticals (CRNX) Ahead of Earnings?
finance.yahoo.com - November 9 at 2:10 PM
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateCrinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - November 6 at 9:29 AM
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary EndpointCrinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
finance.yahoo.com - October 26 at 7:12 AM
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital HyperinsulinismCrinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
finance.yahoo.com - September 21 at 8:38 AM
Crinetics Pharma to advance ACTH antagonist candidate into the clinicCrinetics Pharma to advance ACTH antagonist candidate into the clinic
seekingalpha.com - September 4 at 12:18 PM
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of EndocrinologyCrinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
finance.yahoo.com - September 4 at 12:18 PM
Crinetics Pharmaceuticals to Participate in September Investor ConferencesCrinetics Pharmaceuticals to Participate in September Investor Conferences
finance.yahoo.com - September 3 at 8:43 PM
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateCrinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - August 7 at 9:05 AM
BRIEF-Crinetics Pharmaceuticals Receives Orphan Drug Designation For PaltusotineBRIEF-Crinetics Pharmaceuticals Receives Orphan Drug Designation For Paltusotine
www.reuters.com - July 8 at 6:24 PM
Crinetics Pharmas paltusotine an Orphan Drug in U.S. for growth hormone disorderCrinetics Pharma's paltusotine an Orphan Drug in U.S. for growth hormone disorder
seekingalpha.com - July 8 at 6:24 PM
Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)?Should You Avoid Crinetics Pharmaceuticals, Inc. (CRNX)?
finance.yahoo.com - July 5 at 7:07 PM
Crinetics Pharmaceuticals IncCrinetics Pharmaceuticals Inc
www.bloomberg.com - June 30 at 7:10 PM
Analysts Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging HigherAnalysts' Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging Higher
finance.yahoo.com - June 30 at 9:09 AM
Analysts' Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging HigherAnalysts' Revenue Estimates For Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Are Surging Higher
finance.yahoo.com - June 30 at 9:09 AM
Crinetics Pharmaceuticals, Inc. (CRNX) Shares March Higher, Can It Continue?Crinetics Pharmaceuticals, Inc. (CRNX) Shares March Higher, Can It Continue?
finance.yahoo.com - June 19 at 2:21 PM
BRIEF-Crinetics Confirms Completion For Half Of Enrolled Patients In Ongoing Phase 2 Acrobat Edge Clinical Trial For PaltusotineBRIEF-Crinetics Confirms Completion For Half Of Enrolled Patients In Ongoing Phase 2 Acrobat Edge Clinical Trial For Paltusotine
in.reuters.com - June 11 at 6:03 PM
Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for PaltusotineCrinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
finance.yahoo.com - June 11 at 8:02 AM
Crinetics Pharmaceuticals Appoints Adriana Cabre, MBA, as Vice President of Human ResourcesCrinetics Pharmaceuticals Appoints Adriana Cabre, MBA, as Vice President of Human Resources
www.marketwatch.com - May 27 at 12:12 PM
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human ResourcesCrinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources
finance.yahoo.com - May 27 at 12:12 PM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.